Needham analyst Gil Blum initiated coverage of Absci (ABSI) with a Buy rating and $9 price target Absci “stands out from the pack due to its practical approach” to drug development ...

Truist Financial analyst Srikripa Devarakonda assigned a Buy rating to the stock today. The company’s shares closed last Friday at $2.90.Invest ...

Needham initiates Absci coverage with a Buy rating and a $9 price target, citing robust proprietary technology. Absci’s partnerships with Merck, AstraZeneca, and Almirall provide milestone ...

Absci's ability to generate 'wet-lab data' gives it edge, Needham analsyst says. Shares in a Vancouver-based AI drug creation company Absci soared on Wednesday after an investment firm Needham ...

Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside Needham analyst has initiated coverage on Absci Corporation (NASDAQ:ABSI), a drug and target discovery company that ...

Wednesday, Absci Corp. (NASDAQ:ABSI) shares, currently trading at $3.22, received a positive outlook from Needham as the firm began coverage with a Buy rating and set a price target of $9.00.

In this article, we are going to take a look at where Absci Corporation (NASDAQ:ABSI) stands against the other medical AI stocks. Investments in the global healthcare industry have ramped up ...

We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street's Radar. In this article, we are going to take a look at where Absci Corporation (NASDAQ:ABSI) stands against the other ...

Wednesday, Absci Corp. (NASDAQ:ABSI) shares, currently trading at $3.22, received a positive outlook from Needham as the firm began coverage with a Buy rating and set a price target of $9.00. The ...

Needham analyst has initiated coverage on Absci Corporation (NASDAQ:ABSI), a drug and target discovery company that harnesses deep learning AI and synthetic biology to expand proteins’ therapeutic ...